However , lack of data specifically examining outcomes in PAD patients should not detract from the overwhelming evidence on the benefit of treating hypertension and lowering blood pressure
BACKGROUND Peripheral arterial disease ( PAD ) causes considerable morbidity and mortality .
Hypertension is a risk factor for PAD .
Treatment for hypertension must be compatible with the symptoms of PAD .
Controversy regarding the effects of beta-adrenoreceptor blockade for hypertension in patients with PAD has led many physicians to stop prescribing beta-adrenoreceptor blockers .
Little is known about the effects of other classes of anti-hypertensive drugs in the presence of PAD .
This is the second up date of a Cochrane review first published in 2003 .
OBJECTIVES To determine the effects of anti-hypertensive drugs in patients with both raised blood pressure and symptomatic PAD in terms of the rate of cardiovascular events and death , symptoms of claudication and critical leg ischaemia , and progression of atherosclerotic PAD as measured by ankle brachial index ( ABI ) changes and the need for revascularisation ( reconstructive surgery or angioplasty ) or amputation .
[Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
Authors report results on a comparative multicenter double blind trial carried out to assess the efficacy of Ifenprodil tartrate ( * ) ( 60 mg a.d . ) versus placebo in symptomatic treatment of stable peripheral arterial occlusive disease ( Fontaine stage II ) . Ninety four patients were included in this six months , two parallel group study ( 2 homogeneous groups ) which shows a statistically significant functional improvement in the treatment group versus the placebo group . After six months of treatment , the maximum walking distance (MWD)--main assessment criteria --was 126.0 + /- 18.5 meters in the Ifenprodil group versus 46.4 + /- 20.2 meters in the placebo group ( p = 0.005 ) . This represents an improvement of 62.1 % in the Ifenprodil group versus 21.0 % in the placebo group . An improvement of at least 50 % in MWD was observed in 41.3 % of patients treated by Ifenprodil and in only 12.5 % of patients receiving placebo ( p = 0.002 ) . The evolution of ankle/brachial systolic post exercise index from JO to J180 was not significantly different in the two groups . Clinical and biological tolerance of Ifenprodil tartrate was excellent
However , lack of data specifically examining outcomes in PAD patients should not detract from the overwhelming evidence on the benefit of treating hypertension and lowering blood pressure
BACKGROUND Peripheral arterial disease ( PAD ) causes considerable morbidity and mortality .
Hypertension is a risk factor for PAD .
Treatment for hypertension must be compatible with the symptoms of PAD .
Controversy regarding the effects of beta-adrenoreceptor blockade for hypertension in patients with PAD has led many physicians to stop prescribing beta-adrenoreceptor blockers .
Little is known about the effects of other classes of anti-hypertensive drugs in the presence of PAD .
This is the second up date of a Cochrane review first published in 2003 .
OBJECTIVES To determine the effects of anti-hypertensive drugs in patients with both raised blood pressure and symptomatic PAD in terms of the rate of cardiovascular events and death , symptoms of claudication and critical leg ischaemia , and progression of atherosclerotic PAD as measured by ankle brachial index ( ABI ) changes and the need for revascularisation ( reconstructive surgery or angioplasty ) or amputation .